Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.49 |
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211860 | 0.86 | MGAM (0.58) | MGAMESR2ESR1ALDH1A1CYP1A2 | |
| SCHEMBL2002585 | 0.81 | ESR2 (0.44) | ESR2ESR1ALDH1A1HSD17B14 | |
| SCHEMBL2002271 | 0.78 | CYP1A2 (0.49) | ESR2ESR1ALDH1A1CYP1A2 | |
| Quinaldic Acid SCHEMBL22449356 | 0.77 | MGAM (0.85) | MGAMALDH1A1CYP1A2CYP2C9HSD17B14 | |
| SCHEMBL950437 | 0.77 | MGAM (0.60) | MGAMALDH1A1CYP1A2CYP2C9HSD17B14 | |
| SCHEMBL12405037 | 0.76 | MGAM (0.63) | MGAMALDH1A1 | |
| SCHEMBL69982 | 0.75 | MGAM (0.58) | MGAMESR2ALDH1A1HSD17B14 | |
| SCHEMBL17595151 | 0.74 | MCL1 (0.56) | ESR2ESR1ALDH1A1DHODHMCL1 | |
| SCHEMBL9220609 | 0.74 | MGAM (0.61) | MGAMALDH1A1 | |
| SCHEMBL1000331 | 0.74 | MGAM (0.56) | MGAMALDH1A1BACE1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079307-B1 | FARNESOID X RECEPTOR AGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2079307-A2 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120775-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | MGAM 4671/4885ESR2 246/4885ESR1 362/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | MGAM 4671/4885ESR2 246/4885ESR1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.